Results 21 to 30 of about 11,211 (144)

Breaking the unbreakable: A paediatric case of dolutegravir resistance from KwaZulu-Natal

Southern African Journal of HIV Medicine, 2023
We report a case of dolutegravir resistance in KwaZulu-Natal in a 13-year-old male two years after starting dolutegravir. Resistance most likely developed due to poor adherence as a result of psychosocial issues.
Sibongiseni Malinga, Aabida Khan, Moherndran Archary   +2 more
doaj   +1 more source

Dolutegravir potentiates platelet activation by a calcium-dependent, ionophore-like mechanism

Journal of Immunotoxicology, 2022
Dolutegravir is a highly potent HIV integrase strand transfer inhibitor that is recommended for first-line anti-retroviral treatment in all major treatment guidelines.
Morris Madzime, Annette J. Theron, Ronald Anderson, Gregory R. Tintinger, Helen C. Steel, Pieter W. A. Meyer, Jan G. Nel, Charles Feldman, Theresa M. Rossouw   +8 more
doaj   +1 more source

Neurocognitive improvement in HIV-positive patients treated with dolutegravir-based regimens

South African Journal of Psychiatry, 2023
Background: Neurocognitive disorders due to human immunodeficiency virus (HIV) remain highly prevalent, specifically mild forms despite effective antiretroviral therapy (ART).
Janine Rodrigues, Karishma Lowton
doaj   +1 more source

AntiRetroviral Therapy In Second-line: investigating Tenofovir-lamivudine-dolutegravir (ARTIST): protocol for a randomised controlled trial [version 1; peer review: 2 approved, 1 approved with reservations]

Wellcome Open Research, 2021
Background: Dolutegravir has superior efficacy and tolerability than lopinavir-ritonavir in second-line antiretroviral therapy after failure of a first-line non-nucleoside reverse transcriptase inhibitors-based regimen, when dolutegravir is accompanied ...
Zimasa Gcwabe, Kaneez Sayed, Charlotte Schutz, Olina Ngwenya, Eric Goemaere, Rene Goliath, Amanda Jackson, Rulan Griesel, Andrew Hill, Graeme Meintjes, Tali Cassidy, Claire Keene, Ying Zhao, Gary Maartens   +13 more
doaj   +1 more source

Dolutegravir concentrations in children receiving 3-month weekly isoniazid and rifapentine (3HP) for tuberculosis prevention

Microbiology Spectrum
In Tuberculosis Trials Consortium Study 35, which investigated the optimal dosing and safety of once-weekly isoniazid and rifapentine (3HP) in 69 children requiring tuberculosis preventive therapy, 7 children with HIV received 50 mg of once-daily ...
Ruvarashe J. Madzime, Louvina van der Laan, Samantha du Toit, Shaun Barnabas, Ingrid Courtney, Nicole E. Brown, Rada Savic, Belen P. Solans, Meredith G. Dixon, Lufina Tsirizani, Paolo Denti, Rosanna Boyd, Anneke C. Hesseling   +12 more
doaj   +1 more source

Emergence of Resistance to Integrase Strand Transfer Inhibitors during Dolutegravir Containing Triple-Therapy in a Treatment-Experienced Patient with Pre-Existing M184V/I Mutation

Viruses, 2020
With the current widespread use of dolutegravir in low-income countries, the understanding of the impact of nucleoside reverse transcriptase inhibitor (NRTI-) associated mutations on the efficacy of dolutegravir-containing antiretroviral therapy (ART) is
Dominique L. Braun, Thomas Scheier, Ulrich Ledermann, Markus Flepp, Karin J. Metzner, Jürg Böni, Huldrych F. Günthard   +6 more
doaj   +1 more source

Prevalence of Dietary Supplement Use and Potential Medication Interactions Among Adults with Systemic Lupus Erythematosus

Arthritis Care &Research, Accepted Article.
Objective To characterize the prevalence and correlates of dietary supplement use, identify commonly used supplements, and evaluate potential supplement–medication interactions among adults with systemic lupus erythematosus (SLE). Methods We analyzed cross‐sectional data from 451 adults in the Approaches to Positive, Patient‐centered Experiences of ...
Sarah L. Patterson, Russell Ellyson, Jessica Fitzpatrick, Ghizlane Yaakoubi, Bradley Pearce, S. Sam Lim, Jinoos Yazdany, Laura C. Plantinga   +7 more
wiley   +1 more source

Enhanced Eryptosis Following Exposure to Dolutegravir

Cellular Physiology and Biochemistry, 2016
Background/Aims: The viral integrase enzyme inhibitor dolutegravir is utilized for the treatment of immunodeficiency virus (HIV) infection. Knowledge on cytotoxicity of dolutegravir is limited.
Abdulla Al Mamun Bhuyan, Elena Signoretto, Rosi Bissinger, Florian Lang   +3 more
doaj   +1 more source

Role of Dolutegravir-based antiretroviral treatment in achieving an undetectable HIV-1 viral load among women attending prevention of mother-to-child transmission clinics in Addis Ababa, Ethiopia

SAGE Open Medicine
Objectives: This study aimed to determine the prevalence of detectable HIV-1 viral load and associated factors among pregnant and lactating women on Dolutegravir-based and non-Dolutegravir-based regimens.
Belete Woldesemayat, Yimam Getaneh, Sisay Adane, Ajanaw Yizengaw, Amelework Yilma, Shambel Araya Haile, Kidist Zealiyas   +6 more
doaj   +1 more source

Mutations Located outside the Integrase Gene Can Confer Resistance to HIV-1 Integrase Strand Transfer Inhibitors

mBio, 2017
Resistance to the integrase strand transfer inhibitors raltegravir and elvitegravir is often due to well-identified mutations in the integrase gene. However, the situation is less clear for patients who fail dolutegravir treatment.
Isabelle Malet, Frédéric Subra, Charlotte Charpentier, Gilles Collin, Diane Descamps, Vincent Calvez, Anne-Geneviève Marcelin, Olivier Delelis   +7 more
doaj   +1 more source